FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:732-733 August 18, 2005 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article by Smith, A. D. PubMed Citation

To the Editor: The landmark study by Smith et al. (May 26 issue)¹ shows that measurement of exhaled nitric oxide (Fe_NO) can reduce the dose of inhaled corticosteroids in patients with asthma without impairing control of asthma and, in particular, exacerbations of asthma. Because of the high variability of Fe_NO among both healthy persons and patients with asthma, it may make sense to consider a personalized "best" cutoff Fe_NO level, as seen after the dose-optimization phase or after administration of a dose of oral prednisone. In addition, the relatively high exhalation flow rate used (250 ml per second), as . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.